Da agalsidase beta (r- hαGAL) er et rekombinant protein forventes det at IgG antistoffer udvikles i patienter med ringe eller ingen enzymatisk recidualaktivitet.
Since agalsidase beta (r-hα GAL) is a recombinant protein, the development of IgG antibodies is expected in patients with little or no residual enzyme activity.